曲妥珠单抗联合化疗治疗人表皮生长因子受体-2阳性乳腺癌的临床效果分析  

Analysis of Clinical Effect of Trastuzumab Combined with Chemotherapy in Treatment of Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer

作　　者：孙玮[1] 张勇[1] Sun Wei;Zhang Yong(Shanxi Cancer Hospital,Shanxi Hospital Affiliated to Cancer Hospital of Chinese Academy of Medical Sciences,Affiliated Cancer Hospital of Shanxi Medical University,Taiyuan 030000,Shanxi Province,China)

机构地区：[1]山西省肿瘤医院,中国医学科学院肿瘤医院山西医院,山西医科大学附属肿瘤医院,山西太原030000

出　　处：《中国社区医师》2025年第6期57-59,共3页Chinese Community Doctors

基　　金：山西省高层次人才引进项目(编号:Dr202303);山西省肿瘤医院院所课题项目(编号:202101)。

摘　　要：目的:分析曲妥珠单抗联合化疗治疗人表皮生长因子受体-2(HER-2)阳性乳腺癌的临床效果。方法:选取2021年1月—2023年1月山西省肿瘤医院收治的HER-2阳性乳腺癌患者70例作为研究对象,随机分为两组,每组35例。对照组给予常规化疗,观察组在对照组基础上给予曲妥珠单抗治疗。对比两组治疗效果。结果:治疗后,两组肿瘤标志物水平降低,且观察组比对照组低(P<0.05)。治疗后,两组免疫功能指标水平升高,且观察组高于对照组(P<0.05)。观察组治疗总有效率比对照组高,并发症总发生率低于对照组(P<0.05)。治疗后,两组身体健康、心理健康、社会关系、环境因素评分升高,且观察组比对照组高(P<0.05)。结论:曲妥珠单抗联合化疗治疗HER-2阳性乳腺癌的临床效果较好,能够降低肿瘤标志物水平,改善免疫功能指标,减少并发症,提高患者的生活质量。Objective:To analyze the clinical effect of trastuzumab combined with chemotherapy in treatment of human epidermal growth factor receptor-2(HER-2)positive breast cancer.Methods:From January 2021 to January 2023,70 HER-2 positive breast cancer patients admitted to Shanxi Cancer Hospital were selected as the study subjects.They were randomly divided into two groups,with 35 cases in each group.The control group received conventional chemotherapy,and the observation group received trastuzumab treatment on the basis of the control group.The treatment effects of the two groups were compared.Results:After treatment,the levels of tumor markers in the two groups reduced,and the levels in the observation group were lower than those in the control group(P<0.05).After treatment,the level of immune indicators in the two groups increased,and the levels in the observation group was higher than those in the control group(P<0.05).The total effective rate of treatment in the observation group was higher than that in the control group,and the total incidence of complications in the observation group was lower than that in the control group(P<0.05).After treatment,the scores of physical health,mental health,social relationship and environmental factors in the two groups increased,and the scores in the observation group were higher than those in the control group(P<0.05).Conclusion:Trastuzumab combined with chemotherapy has a good clinical effect in the treatment of HER-2 positive breast cancer,and can reduce the levels of tumor markers,improve immune function indicators,reduce complications and improve the quality of life of patients.

关 键 词：曲妥珠单抗 靶向治疗 人表皮生长因子受体-2阳性乳腺癌 血清肿瘤标志物 免疫功能 

分 类 号：R737.9[医药卫生—肿瘤]